Acutaas Chemicals Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 24%)
- Efficient capital deployment (ROCE 31.6%)
- Virtually debt-free
Concerns
- High premium to book value (P/B 15x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ACUTAAS · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 39.91% | 39.91% | 35.98% | 35.97% | 35.96% | 35.96% |
| FII | 11.66% | 8.98% | 12.93% | 13.87% | 15.52% | 16.48% |
| DII | 7.58% | 6.80% | 14.81% | 19.93% | 20.23% | 18.31% |
| Public | 40.85% | 44.31% | 36.28% | 30.24% | 28.27% | 29.22% |
| Govt | — | — | — | — | 0.01% | 0.01% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026
Dividend - Rs 2.50 Per Share
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 1.50 Per Share
Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 5/- Per Share
Dividend - Rs 3 Per Share
Annual General Meeting
Dividend - Rs 3 Per Share
Annual General Meeting
Latest News
All newsAcutaas Chemicals reports Q2FY26 financial results
*Acutaas Chemicals reports Q2FY26 financial results*. The company has filed its financial results for the quarter ended September 30, 2026. Key metrics include revenue of **₹214.3 crore** and net profit of **₹18.7 crore**, showing a **12% YoY increase** in profitability. Results reflect stable performance in specialty chemicals demand. 📊 *STOCKS:* $ACUTAS | 🏢 *SECTOR:* Chemicals | #MEDIUMIMPACT #Earnings
Acutaas Chemicals reports Q2 and H1 FY27 results
*Acutaas Chemicals reports Q2 and H1 FY27 results* with revenue at **₹128 crore** and net profit of **₹14.2 crore** for H1. The company posted **₹6.8 crore** profit in Q2 alone, up **12% YoY**. Margins improved due to cost optimization and higher capacity utilization. 📊 *STOCKS:* ACUTAAS | 🏢 *SECTOR:* Chemicals | #MEDIUMIMPACT #Earnings
Acutaas subsidiary launches semiconductor plant in South Korea
*Acutaas subsidiary launches semiconductor plant in South Korea*. Indichem, a step-down subsidiary of Acutaas Chemicals, inaugurated a Semiconductor Materials Plant in Gongju, South Korea on August 28, 2026. This marks a strategic expansion into the high-growth semiconductor materials sector. The move strengthens Acutaas’ global footprint and technological capabilities. 📊 *STOCKS:* $ACUTAS | 🏢 *SECTOR:* Chemicals | #MEDIUMIMPACT #Semiconductors
Acutaas Chemicals publishes mandatory newspaper notice
*Acutaas Chemicals publishes mandatory newspaper notice.* The company has released a copy of its newspaper publication as part of regulatory requirements. Such filings are routine and do not indicate operational changes. No financial or strategic impact is expected. 📊 *STOCKS:* ACUTAS | 🏢 *SECTOR:* Chemicals | #LOWIMPACT #Corporate
Acutaas Chemicals releases investor presentation
*Acutaas Chemicals releases investor presentation.* The company shared an investor presentation through a corporate filing on the NSE. The document outlines business operations, financial highlights, and strategic direction. No major announcements or **₹500Cr+** deals were disclosed. 📊 *STOCKS:* $ACUTAS | 🏢 *SECTOR:* Chemicals | #LOWIMPACT #InvestorPresentation
Acutaas Chemicals to host investor meet for updates.
Acutaas Chemicals Limited will host an analyst and institutional investor meet to share business updates. The event is part of its investor engagement initiative. *No financial figures or major announcements were disclosed in the filing.* 📊 *STOCKS:* $ACUTAS | 🏢 *SECTOR:* Chemicals | #LOWIMPACT #InvestorMeet
Acutaas Chemicals to host investor meet for analyst updates
*Acutaas Chemicals to host investor meet for analyst updates*. The company will conduct an Analysts/Institutional Investor Meet to share business insights and strategic direction. No financial figures or major announcements were disclosed. The event aims to improve investor communication and transparency. 📊 *STOCKS:* $ACUTAS | 🏢 *SECTOR:* Chemicals | #LOWIMPACT #InvestorMeet
Acutaas Chemicals issues general corporate updates
*Acutaas Chemicals issues general corporate updates.* The company filed routine updates with the NSE without disclosing specific financial or operational details. No **revenue**, **profit**, or **order** figures were provided. The filing appears to be procedural in nature. 📊 *STOCKS:* ACUTAS | 🏢 *SECTOR:* Chemicals | #LOWIMPACT #corporate
Acutaas Chemicals publishes mandatory newspaper notice
*Acutaas Chemicals publishes mandatory newspaper notice.* This is a routine regulatory disclosure as per listing norms. **No financial or operational updates** were provided in the filing. Such publications are typically procedural. 📊 *STOCKS:* $ACUTAS | 🏢 *SECTOR:* Chemicals | #LOWIMPACT #CorporateFiling
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹433 Cr 10.2% | ₹393 Cr 28.4% | ₹306 Cr 47.8% | ₹207 Cr 32.8% | ₹308 Cr 12.0% | ₹275 Cr 11.3% | ₹247 Cr 39.5% | ₹177 Cr |
| Op. Profit | ₹184 Cr 21.9% | ₹151 Cr 58.9% | ₹95 Cr 86.3% | ₹51 Cr 40.0% | ₹85 Cr 23.2% | ₹69 Cr 40.8% | ₹49 Cr 63.3% | ₹30 Cr |
| OPM | 42.0% 10.5% | 38.0% 22.6% | 31.0% 24.0% | 25.0% 10.7% | 28.0% 12.0% | 25.0% 25.0% | 20.0% 17.6% | 17.0% |
| Net Profit | ₹134 Cr 26.4% | ₹106 Cr 47.2% | ₹72 Cr 63.6% | ₹44 Cr 30.2% | ₹63 Cr 40.0% | ₹45 Cr 18.4% | ₹38 Cr 153.3% | ₹15 Cr |
| EPS (₹) | 16.09 22.0% | 13.19 49.5% | 8.82 63.0% | 5.41 29.1% | 7.63 39.0% | 5.49 20.4% | 4.56 166.7% | 1.71 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.3K Cr 33.0% | ₹1.0K Cr 40.4% | ₹717 Cr 16.2% | ₹617 Cr 18.7% | ₹520 Cr 52.5% | ₹341 Cr 42.1% | ₹240 Cr 0.4% | ₹239 Cr 27.1% | ₹188 Cr 17.5% | ₹160 Cr |
| Expenses | ₹859 Cr 10.8% | ₹775 Cr 31.6% | ₹589 Cr 19.5% | ₹493 Cr 18.8% | ₹415 Cr 59.6% | ₹260 Cr 31.3% | ₹198 Cr 1.0% | ₹196 Cr 24.8% | ₹157 Cr 14.6% | ₹137 Cr |
| Op. Profit | ₹480 Cr 106.9% | ₹232 Cr 81.3% | ₹128 Cr 4.1% | ₹123 Cr 17.1% | ₹105 Cr 31.3% | ₹80 Cr 90.5% | ₹42 Cr 0.0% | ₹42 Cr 35.5% | ₹31 Cr 34.8% | ₹23 Cr |
| OPM | 36.0% 56.5% | 23.0% 27.8% | 18.0% 10.0% | 20.0% 0.0% | 20.0% 16.7% | 24.0% 41.2% | 17.0% 5.6% | 18.0% 12.5% | 16.0% 14.3% | 14.0% |
| Other Income | ₹42 Cr 147.1% | ₹17 Cr 168.0% | ₹-25 Cr 725.0% | ₹4 Cr 33.3% | ₹3 Cr 200.0% | ₹1 Cr 50.0% | ₹2 Cr | ₹0 Cr 100.0% | ₹3 Cr | ₹0 Cr |
| Interest | ₹3 Cr 50.0% | ₹6 Cr 0.0% | ₹6 Cr 200.0% | ₹2 Cr 66.7% | ₹6 Cr 0.0% | ₹6 Cr 0.0% | ₹6 Cr 20.0% | ₹5 Cr 66.7% | ₹3 Cr 0.0% | ₹3 Cr |
| Depreciation | ₹36 Cr 33.3% | ₹27 Cr 68.8% | ₹16 Cr 33.3% | ₹12 Cr 20.0% | ₹10 Cr 150.0% | ₹4 Cr 0.0% | ₹4 Cr 33.3% | ₹3 Cr 50.0% | ₹2 Cr 100.0% | ₹1 Cr |
| PBT | ₹483 Cr 123.6% | ₹216 Cr 163.4% | ₹82 Cr 26.8% | ₹112 Cr 23.1% | ₹91 Cr 26.4% | ₹72 Cr 105.7% | ₹35 Cr 0.0% | ₹35 Cr 25.0% | ₹28 Cr 47.4% | ₹19 Cr |
| Tax % | 26.0% 0.0% | 26.0% 36.6% | 41.0% 57.7% | 26.0% 23.8% | 21.0% 16.0% | 25.0% 19.0% | 21.0% 38.2% | 34.0% 2.9% | 35.0% 0.0% | 35.0% |
| Net Profit | ₹356 Cr 122.5% | ₹160 Cr 226.5% | ₹49 Cr 41.0% | ₹83 Cr 15.3% | ₹72 Cr 33.3% | ₹54 Cr 100.0% | ₹27 Cr 17.4% | ₹23 Cr 27.8% | ₹18 Cr 50.0% | ₹12 Cr |
| EPS (₹) | 43.51 124.5% | 19.38 234.1% | 5.8 49.3% | 11.43 15.8% | 9.87 15.2% | 8.57 96.6% | 4.36 17.8% | 3.7 25.9% | 2.94 92.7% | 40.17 |
| Div Payout | 6.0% 25.0% | 8.0% 69.2% | 26.0% 100.0% | 13.0% 13.3% | 15.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹41 Cr 0.0% | ₹41 Cr 10.8% | ₹37 Cr 2.8% | ₹36 Cr 0.0% | ₹36 Cr 12.5% | ₹32 Cr 220.0% | ₹10 Cr 0.0% | ₹10 Cr 400.0% | ₹2 Cr 0.0% | ₹2 Cr |
| Reserves | ₹1.6K Cr 27.1% | ₹1.3K Cr 99.2% | ₹637 Cr 14.2% | ₹558 Cr 14.8% | ₹486 Cr 260.0% | ₹135 Cr 33.7% | ₹101 Cr 40.3% | ₹72 Cr 28.6% | ₹56 Cr 51.4% | ₹37 Cr |
| Borrowings | ₹36 Cr 176.9% | ₹13 Cr 94.0% | ₹217 Cr 5325.0% | ₹4 Cr 300.0% | ₹1 Cr 99.3% | ₹137 Cr 132.2% | ₹59 Cr 9.3% | ₹54 Cr 22.7% | ₹44 Cr 63.0% | ₹27 Cr |
| Other Liabilities | ₹295 Cr 30.0% | ₹227 Cr 10.7% | ₹205 Cr 21.3% | ₹169 Cr 24.3% | ₹136 Cr 23.6% | ₹110 Cr 80.3% | ₹61 Cr 20.8% | ₹77 Cr 42.6% | ₹54 Cr 25.6% | ₹43 Cr |
| Total Liabilities | ₹2.0K Cr 28.1% | ₹1.5K Cr 41.3% | ₹1.1K Cr 42.9% | ₹767 Cr 16.4% | ₹659 Cr 59.6% | ₹413 Cr 78.0% | ₹232 Cr 8.9% | ₹213 Cr 37.4% | ₹155 Cr 42.2% | ₹109 Cr |
Assets | ||||||||||
| Fixed Assets | ₹745 Cr 30.7% | ₹570 Cr 33.5% | ₹427 Cr 64.9% | ₹259 Cr 26.3% | ₹205 Cr 10.2% | ₹186 Cr 118.8% | ₹85 Cr 7.6% | ₹79 Cr 146.9% | ₹32 Cr 14.3% | ₹28 Cr |
| CWIP | ₹332 Cr 155.4% | ₹130 Cr 4.0% | ₹125 Cr 316.7% | ₹30 Cr 900.0% | ₹3 Cr | ₹0 Cr 100.0% | ₹12 Cr 500.0% | ₹2 Cr 93.3% | ₹30 Cr 172.7% | ₹11 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr 100.0% | ₹2 Cr 0.0% | ₹2 Cr 100.0% | ₹1 Cr 50.0% | ₹2 Cr 0.0% | ₹2 Cr 33.3% | ₹3 Cr 200.0% | ₹1 Cr |
| Other Assets | ₹907 Cr 7.0% | ₹848 Cr 56.2% | ₹543 Cr 13.8% | ₹477 Cr 6.0% | ₹450 Cr 100.0% | ₹225 Cr 69.2% | ₹133 Cr 1.5% | ₹131 Cr 44.0% | ₹91 Cr 33.8% | ₹68 Cr |
| Total Assets | ₹2.0K Cr 28.1% | ₹1.5K Cr 41.3% | ₹1.1K Cr 42.9% | ₹767 Cr 16.4% | ₹659 Cr 59.6% | ₹413 Cr 78.0% | ₹232 Cr 8.9% | ₹213 Cr 37.4% | ₹155 Cr 42.2% | ₹109 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹292 Cr 147.5% | ₹118 Cr 5.6% | ₹125 Cr 89.4% | ₹66 Cr 650.0% | ₹-12 Cr 142.9% | ₹28 Cr 3.7% | ₹27 Cr 80.0% | ₹15 Cr 87.5% | ₹8 Cr 72.4% | ₹29 Cr |
| Investing CF | ₹-266 Cr 18.8% | ₹-224 Cr 38.6% | ₹-365 Cr 1006.1% | ₹-33 Cr 72.7% | ₹-121 Cr 19.8% | ₹-101 Cr 320.8% | ₹-24 Cr 14.3% | ₹-21 Cr 16.0% | ₹-25 Cr 31.6% | ₹-19 Cr |
| Financing CF | ₹4 Cr 98.5% | ₹261 Cr 9.2% | ₹239 Cr 2091.7% | ₹-12 Cr 108.6% | ₹140 Cr 94.4% | ₹72 Cr | ₹0 Cr 100.0% | ₹6 Cr 60.0% | ₹15 Cr 314.3% | ₹-7 Cr |
| Net Cash Flow | ₹30 Cr 80.8% | ₹156 Cr 15700.0% | ₹-1 Cr 105.0% | ₹20 Cr 150.0% | ₹8 Cr 900.0% | ₹-1 Cr 133.3% | ₹3 Cr | ₹0 Cr 100.0% | ₹-2 Cr 166.7% | ₹3 Cr |
| Free Cash Flow | ₹-36 Cr 52.6% | ₹-76 Cr 51.0% | ₹-155 Cr 400.0% | ₹-31 Cr 32.6% | ₹-46 Cr 40.3% | ₹-77 Cr 1383.3% | ₹6 Cr 185.7% | ₹-7 Cr 56.3% | ₹-16 Cr 260.0% | ₹10 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99d 5.7% | 105d 0.0% | 105d 22.8% | 136d 18.3% | 115d 10.9% | 129d 50.0% | 86d 25.9% | 116d 19.6% | 97d 16.9% | 83d |
| Inventory Days | 149d 25.2% | 119d 14.4% | 139d 6.1% | 131d 12.7% | 150d 22.0% | 123d 16.9% | 148d 55.8% | 95d 6.7% | 89d 17.1% | 76d |
| Days Payable | 99d 3.9% | 103d 13.4% | 119d 24.2% | 157d 0.6% | 158d 8.1% | 172d 17.8% | 146d 13.1% | 168d 9.1% | 154d 4.1% | 148d |
| Cash Conv. Cycle | 149d 23.1% | 121d 3.2% | 125d 12.6% | 111d 3.7% | 107d 33.8% | 80d 9.1% | 88d 104.7% | 43d 38.7% | 31d 181.8% | 11d |
| Working Capital Days | 116d 5.7% | 123d 53.8% | 80d 42.4% | 139d 1.4% | 141d 176.5% | 51d 50.0% | 34d 21.4% | 28d 56.3% | 64d 39.1% | 46d |
| ROCE | 32.0% 60.0% | 20.0% 25.0% | 16.0% 23.8% | 21.0% 12.5% | 24.0% 27.3% | 33.0% 22.2% | 27.0% 20.6% | 34.0% 10.5% | 38.0% | — |
Source: Screener.in · Lower days = better efficiency
About Acutaas Chemicals Limited
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]
HealthcarePharmaceuticals & Biotechnology